New combo therapy shows promise for tough melanomas

NCT ID NCT04109456

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called IN10018, alone or with other medicines, in 51 adults with advanced melanoma that had spread. The main goal was to check safety and how the body handles the drug. The study included people with two hard-to-treat types of melanoma: uveal melanoma and NRAS-mutant melanoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • MD Anderson

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • St Vincent Hospital Sydney

    Sydney, New South Wales, Australia

  • Sylvester Comprehensive Cancer Center.

    Miami, Florida, 33136, United States

  • The Alfred Hospital

    Melbourne, Victoria, Australia